The mixed results are a blow for bepranemab and for related antibodies that target a mid-region epitope on tau. But exploratory analyses of the results hint at a path forward for these candidates.

The company aims to supercharge antibody treatments using specially designed protein “cages” that multiply their effects, opening up new opportunities in drug development. The company was spun ...

Ueda is holding an expandable toy that he uses to demonstrate how the company’s computationally designed Antibody Cages work. (GeekWire Photo / Alan Boyle) Three weeks after University of ...

Therapeutic antibodies are an important alternative option, but resistance has developed owing to the emergence of viral variants. A new paper in Cell reports the development of an antibody with ...

Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi 465-8603, Japan Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural ...

Scientists have developed an innovative antibody platform aimed at tackling one of the greatest challenges in treating rapidly evolving viruses like SARS-CoV-2: their ability to mutate and evade ...

About clesrovimab (MK-1654) Clesrovimab (MK-1654) is an investigational, extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV. Clesrovimab is ...

A thyroglobulin antibody test measures antibodies against thyroglobulin, a protein found in thyroid cells. In people with an autoimmune thyroid condition, the immune system mistakenly produces ...

This is because some drugs work in more than one way and belong to more than one group. Checkpoint inhibitors are also described as a type of monoclonal antibody or targeted treatment. Our immune ...

To investigate whether K-Ras4a could also be regulated by SIRT2 through deacetylation, we examined its acetylation level using a pan-specific acetyl lysine antibody. Acetylation was not detected on ...